Introduction and Overview of ACT Consortium research on safety: Professor David Schellenberg (London School of Hygiene & Tropical Medicine, UK) and Professor David Lalloo (Liverpool School of Tropical Medicine, UK)
Clinical trials are not suitable to identify rare, potentially serious adverse effects of drugs, or to define their safety in high risk populations.
Artemisinin-based combination therapies (or ACTs) are considered safe, but there are concerns over their potential to cause damage to parts of the brain. There is also a concern about their safety in patients infected with HIV.
Collating safety data is a challenge in Africa, where most antimalarials are used and more vulnerable populations reside.
The Safety Data Collection Tools for Real-World Reporting developed by the ACT Consortium are the first step to providing more resources for researchers seeking user-friendly methods to evaluate antimalarial safety.